Third Harmonic Bio reports $269.1M cash, files IND for THB335, Q4 net loss narrows

Third Harmonic Bio, Inc.

Cash and equivalents $269.1M as of Dec 31, 2023; expected to fund operations through at least 2026.
Net loss for Q4 2023 was $6.8M versus $11.5M in Q4 2022; full-year net loss $30.8M.
R&D expenses decreased to $5.9M in Q4 2023 from $9.3M year-over-year.
U.S. IND filed for THB335, a potential first-in-class oral KIT inhibitor for chronic spontaneous urticaria.
Phase 1 SAD/14-day MAD study in healthy volunteers anticipated to start in Q2 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Third Harmonic Bio, Inc. reported fourth quarter and full year ended December 31, 2023 results: net income Net loss for the three months ended December 31, 2023 decreased to $6.8 million from a net loss of $11.5 million for the.

Period: fourth quarter and full year ended December 31, 2023
Net income: Net loss for the three months ended December 31, 2023 decreased to $6.8 million from a net loss of $11.5 million for the
Result: reported results

Exact text from the filing

Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results

View on SEC.gov

Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-036162

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.